TCIM
AIMT

TIAA CREF Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

TIAA CREF Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.75M Sell
78,191
-3,777
-5% -$88.9K ﹤0.01% 2072
2018
Q4 		$1.96M Sell
81,968
-2,289
-3% -$59.2K ﹤0.01% 1965
2018
Q3 		$2.3M Sell
84,257
-7,033
-8% -$199K ﹤0.01% 2054
2018
Q2 		$2.46M Buy
91,290
+5,560
+6% +$170K ﹤0.01% 2057
2018
Q1 		$2.73M Buy
85,730
+266
+0.3% +$9.36K ﹤0.01% 1932
2017
Q4 		$3.23M Sell
85,464
-8,521
-9% -$275K ﹤0.01% 1872
2017
Q3 		$2.33M Sell
93,985
-1,262
-1% -$27.2K ﹤0.01% 2077
2017
Q2 		$1.96M Buy
95,247
+24,226
+34% +$462K ﹤0.01% 2192
2017
Q1 		$1.54M Sell
71,021
-8,197
-10% -$168K ﹤0.01% 2290
2016
Q4 		$1.62M Sell
79,218
-4,510
-5% -$92.2K ﹤0.01% 2295
2016
Q3 		$1.26K Sell
83,728
-370
-0.4% -$4.99K ﹤0.01% 2419
2016
Q2 		$910K Buy
84,098
+50,519
+150% +$686K ﹤0.01% 2565
2016
Q1 		$455K Sell
33,579
-17,210
-34% -$268K ﹤0.01% 2817
2015
Q4 		$937K Buy
50,789
+17,210
+51% +$318K ﹤0.01% 2622
2015
Q3 		$850K Buy
+33,579
New +$785K ﹤0.01% 2664

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

TIAA CREF Investment Management's AIMT Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Aimmune Therapeutics (AIMT) stake by 4.6% in Q1 2019, selling an estimated $88.9K and leaving 78,191 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

TIAA CREF Investment Management first reported a position in AIMT in Q3 2015 and has held it in 15 quarters since. The position peaked at $3.23M in Q4 2017. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

  • TIAA CREF Investment Management held 78,191 shares of Aimmune Therapeutics worth $1.75M as of Q1 2019.
  • TIAA CREF Investment Management sold 3,777 Aimmune Therapeutics shares in Q1 2019, an estimated $88.9K.
  • Aimmune Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2072 holding.
  • TIAA CREF Investment Management first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 15 quarters since.
  • TIAA CREF Investment Management's Aimmune Therapeutics position peaked at $3.23M in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.